Authors’ reply

摘要

We thank Dr Temmingh for his interest in our paper.[1][1] The use of sulpiride in CUtLASS-1 was discussed in the original report[2][2] and subsequent correspondence.[3][3] The Cochrane review of sulpiride in schizophrenia[4][4] concluded that extrapyramidal side-effects (EPS) may be less frequent